Ansell Ltd
ASX:ANN

Watchlist Manager
Ansell Ltd Logo
Ansell Ltd
ASX:ANN
Watchlist
Price: 36.01 AUD -0.96% Market Closed
Market Cap: 5.2B AUD

Ansell Ltd
Investor Relations

Ansell Ltd, with its origins tracing back to the innovative entrepreneurship of founder Eric Norman Ansell in the early 20th century, has established itself as a global leader in protection solutions. Initially starting with condoms and expanding into gloves, the company now boasts a diversified portfolio encompassing protective solutions for industrial workers and healthcare professionals. This growth reflects Ansell's adept ability to identify and respond to evolving market demands. The company has capitalized on its deep expertise in material science and product design, underpinning its operations with a robust research and development framework that continually pushes the boundaries of product efficacy and safety.

Instrumental to its business model is Ansell’s alignment with regulatory standards across its wide geographical footprint, ensuring that its products not only meet but often exceed industry and safety specifications. By navigating complex regulations and maintaining high standards, Ansell has cemented relationships with a broad clientele base drawn from healthcare providers, industrial entities, and retail channels. The company thrives by leveraging its extensive distribution network and strategic acquisitions, enhancing its global presence. Through innovative product lines, such as cut-protection gloves and surgical solutions, Ansell generates revenue by addressing critical safety needs, ensuring that both individuals and organizations can rely on its products to protect them in the most demanding environments.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2023
Call Date
Aug 13, 2023
AI Summary
Q4 2023

EPS Guidance: Ansell delivered FY '23 EPS at the low end of its original guidance, reflecting challenging conditions, and guided FY '24 EPS to $0.92–$1.12, below pre-pandemic levels.

Revenue Drivers: Industrial organic revenue grew 4.3%, led by Mechanical at 5%, while Healthcare was hit by customer destocking and a 30% sales drop in Exam/Single Use.

Margins: Group EBIT margins improved, especially in Industrial, benefiting from price increases; GPADE margin rose to nearly 31%.

Productivity Program: Ansell launched a $40–$50 million, three-year accelerated productivity investment program targeting $45 million in annual savings by FY '26.

Cash Conversion: FY '23 cash conversion improved in H2 (93%), with expectations for >90% in FY '24 as inventory unwinds.

CapEx and Buybacks: FY '24 CapEx guided to $60–$80 million, including continued investment in India and ESG; $50 million buyback planned.

Supply Chain & Inventory: Significant supply chain, digital, and in-sourcing progress reported, with inventory reduction a focus for FY '24.

Macro & Outlook: No signs of recession yet in key markets, but FX and inflation remain headwinds, with normalization expected by FY '25.

Key Financials
EPS
Delivered at the low end of guidance for FY '23
Organic Revenue Growth (Industrial)
4.3%
Organic Revenue Growth (Mechanical)
5%
Exam/Single Use Revenue Decline
Down almost 30% year-on-year
GPADE Margin
Nearly 31%
SG&A as % of Sales
Just over 18%
Effective Tax Rate
Just over 21%
CapEx
Just under $70 million in FY '23
Cash Conversion (H2 FY '23)
93%
Net Debt to EBITDA
Just above 1x
Pretax ROCE
11%
Share Buyback
$50 million targeted in next 12 months
Earnings Call Recording
Other Earnings Calls
2023

Management

Mr. Neil I. Salmon ACMA, BA
MD, CEO & Director
No Bio Available
Mr. Zubair Javeed
Chief Financial Officer
No Bio Available
Mr. Rikard Fröberg MA, MS
Chief Product & Marketing Officer
No Bio Available
Mr. John Marsden
Chief Operations & Supply Chain Officer
No Bio Available
Ms. Deanna Johnston
Chief Information Officer
No Bio Available
Mr. Michael Evans
Senior Director of Investor Relations and Corporate M&A
No Bio Available
Mr. Philippe H. Rommel
General Counsel
No Bio Available
Ms. Charlotte Doll
Chief Human Resource Officer
No Bio Available
Mr. Francois Le Jeune BS, MBA, MS
Chief Commercial Officer of Guardian Administration
No Bio Available
Mr. Augusto M. Accorsi
Chief Commercial Officer of EMEA & APAC
No Bio Available

Contacts

Address
VICTORIA
RICHMOND
L 3 678 Victoria Street
Contacts
+61392707270.0
www.ansell.com